Verve Therapeutics
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes
Post navigation
Previous Post
Previous
Verve raises another $63m to develop gene-editing treatment for heart disease
Next Post
Next
Verve banks $63M to move gene-editing heart attack treatment toward clinic
Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
◄ Back
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact Us